MRC Technology appoints technology transfer director
Andrew Farquharson has been appointed Director of Technology Transfer from 1 September.
Twitter outputted an error:
Invalid or expired token..
Invalid or expired token..
Brain inflammation targeted in first drug discovery project from £3m Dementia Consortium
Funding worth nearly half a million pounds will unite academics at the University of Southampton with drug discovery experts at the medical research charity MRC Technology, to target the immune system in the hunt for new treatments for Alzheimer's disease.
MRC Technology and Peptinnovate collaborate on therapeutics for bone diseases
Collaboration to assess the therapeutic potential in bone diseases of Peptinnovate’s unique peptides derived from the bacterium Mycobacterium tuberculosis.
Poster prize for presentation at Chemistry in Health Conference
Ela Smiljanic-Hurley's poster presentation at the Chemistry in Health Conference 2015, held on 26 May at the…
Dementia care digital platform launched by partnership including MRC Technology
Brain health company IXICO launched a digital platform, Project Cygnus, to support patients with the diseases that cause dementia. IXICO is the lead partner in the project, working alongside MRC Technology, The Northern Health Science Alliance Network (NHSA) and several NHS Trusts in the North of England. The project is part-funded by Innovate UK (formerly the Technology Strategy Board).
MRC Technology collaborates with NYU School of Medicine to develop biologics for inflammatory bone disease
MRC Technology and NYU School of Medicine have signed an agreement to develop an antibody for the prevention of inflammatory osteolysis (bone breakdown).
MRC Technology appoints Finance Director
MRC Technology has appointed Andrew Mercieca as its Finance Director from 1 April 2015. Andrew joined the company as Interim Finance Director in August 2014.
MRC Technology Negotiates Licence Deal with Quantifoil Micro Tools GmbH for Ultrastable Gold Support (UltrAuFoil) Technology
MRC Technology announced it has negotiated a licence for ultrastable gold supports developed at the MRCLaboratory of Molecular Biology, with Quantifoil Micro Tools GmbH (Quantifoil). Under this licence, Quantifoil will manufacture and market the gold supports (UltrAuFoil™).
Immunotherapy drugs could herald new era in cancer treatment
Immunotherapy, which uses the body’s own defence mechanism, is at long last becoming accepted as a frontline treatment for cancer, taking its place alongside conventional chemotherapy and radiation-based treatments.